Parag Mahale1, Chinenye Ugoji2, Eric A Engels1, Meredith S Shiels1, Sally Peprah1, Lindsay M Morton3. 1. Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda. 2. Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore. 3. Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
OBJECTIVE(S): HIV-infected people have increased cancer risk. Lymphoma survivors have an increased risk of certain second primary cancers in the general population, but second cancer risk among HIV-infected people is poorly understood. Herein, we characterized the risk of cancers following lymphoid malignancies among HIV-infected people. DESIGN: Population-based linkage of HIV and cancer registries. METHODS: We used data from the US HIV/AIDS Cancer Match Study (1996-2015) and evaluated the risk of first nonlymphoid malignancy in Cox regression models, with first lymphoid malignancy diagnosis as a time-dependent variable. RESULTS: Among 531 460 HIV-infected people included in our study, 6513 first lymphoid and 18 944 first nonlymphoid malignancies were diagnosed. Risk of nonlymphoid cancer following a lymphoid malignancy was increased overall [adjusted hazard ratio (aHR) = 2.7; 95% confidence interval (CI) = 2.3--3.2], and specifically for cancers of the oral cavity (aHR = 2.6; 95% CI = 1.2-5.5), colon (2.4; 1.1-5.0), rectum (3.6; 1.9-6.7), anus (3.6; 2.5-5.1), liver (2.0; 1.2-3.5), lung (1.6; 1.1-2.4), vagina/vulva (6.1; 2.3-16.3), and central nervous system (5.0; 1.6-15.6), Kaposi sarcoma (4.6; 3.4-6.2), and myeloid malignancies (9.7; 6.1-15.4). After additional adjustment for prior AIDS diagnosis and time since HIV diagnosis, aHRs were attenuated overall (aHR = 1.7; 95% CI = 1.5-2.0) and remained significant for cancers of the rectum, anus, and vagina/vulva, Kaposi sarcoma, and myeloid malignancies. CONCLUSION: HIV-infected people with lymphoid malignancies have an increased risk of subsequent non-lymphoid cancers. As risks remained significant after adjustment for time since HIV diagnosis and prior AIDS diagnosis, it suggests that immunosuppression may explain some, but not all, of these risks.
OBJECTIVE(S): HIV-infected people have increased cancer risk. Lymphoma survivors have an increased risk of certain second primary cancers in the general population, but second cancer risk among HIV-infected people is poorly understood. Herein, we characterized the risk of cancers following lymphoid malignancies among HIV-infected people. DESIGN: Population-based linkage of HIV and cancer registries. METHODS: We used data from the US HIV/AIDS Cancer Match Study (1996-2015) and evaluated the risk of first nonlymphoid malignancy in Cox regression models, with first lymphoid malignancy diagnosis as a time-dependent variable. RESULTS: Among 531 460 HIV-infected people included in our study, 6513 first lymphoid and 18 944 first nonlymphoid malignancies were diagnosed. Risk of nonlymphoid cancer following a lymphoid malignancy was increased overall [adjusted hazard ratio (aHR) = 2.7; 95% confidence interval (CI) = 2.3--3.2], and specifically for cancers of the oral cavity (aHR = 2.6; 95% CI = 1.2-5.5), colon (2.4; 1.1-5.0), rectum (3.6; 1.9-6.7), anus (3.6; 2.5-5.1), liver (2.0; 1.2-3.5), lung (1.6; 1.1-2.4), vagina/vulva (6.1; 2.3-16.3), and central nervous system (5.0; 1.6-15.6), Kaposi sarcoma (4.6; 3.4-6.2), and myeloid malignancies (9.7; 6.1-15.4). After additional adjustment for prior AIDS diagnosis and time since HIV diagnosis, aHRs were attenuated overall (aHR = 1.7; 95% CI = 1.5-2.0) and remained significant for cancers of the rectum, anus, and vagina/vulva, Kaposi sarcoma, and myeloid malignancies. CONCLUSION: HIV-infected people with lymphoid malignancies have an increased risk of subsequent non-lymphoid cancers. As risks remained significant after adjustment for time since HIV diagnosis and prior AIDS diagnosis, it suggests that immunosuppression may explain some, but not all, of these risks.
Authors: Elizabeth C Moser; Evert M Noordijk; Flora E van Leeuwen; Joke W Baars; José Thomas; Patrice Carde; Jacobus H Meerwaldt; Martine van Glabbeke; Hanneke C Kluin-Nelemans Journal: Haematologica Date: 2006-10-17 Impact factor: 9.941
Authors: Harrys A Torres; Jeff Hosry; Parag Mahale; Minas P Economides; Ying Jiang; Anna S Lok Journal: Hepatology Date: 2017-11-13 Impact factor: 17.425
Authors: Lindsay M Morton; Patricia Hartge; Theodore R Holford; Elizabeth A Holly; Brian C H Chiu; Paolo Vineis; Emanuele Stagnaro; Eleanor V Willett; Silvia Franceschi; Carlo La Vecchia; Ann Maree Hughes; Wendy Cozen; Scott Davis; Richard K Severson; Leslie Bernstein; Susan T Mayne; Fred R Dee; James R Cerhan; Tongzhang Zheng Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-04 Impact factor: 4.254
Authors: Nadejda Y Mudie; Anthony J Swerdlow; Craig D Higgins; Paul Smith; Zongkai Qiao; Barry W Hancock; Peter J Hoskin; David C Linch Journal: J Clin Oncol Date: 2006-03-06 Impact factor: 44.544
Authors: Raúl U Hernández-Ramírez; Li Qin; Haiqun Lin; Wendy Leyden; Romain S Neugebauer; Keri N Althoff; Chad J Achenbach; Nancy A Hessol; Gypsyamber D'Souza; Kelly A Gebo; M John Gill; Surbhi Grover; Michael A Horberg; Jun Li; W Christopher Mathews; Angel M Mayor; Lesley S Park; Charles S Rabkin; Kate Salters; Amy C Justice; Richard D Moore; Eric A Engels; Michael J Silverberg; Robert Dubrow Journal: Lancet HIV Date: 2019-02-27 Impact factor: 16.070